@article{e25176e162f44be4a2446d56e1b742a6,
title = "Depression, antidepressants and low hemoglobin level in the Paris Prospective Study III: A cross-sectional analysis",
abstract = "Anemia is known to be associated with depression both in community and clinical populations. However, it is still unknown if this association depends or not on antidepressant intake. We investigated the respective association of depression and antidepressant intake with low hemoglobin level in a large community-based cohort. In 8640 volunteers aged 50 to 75 recruited between June 2008 and June 2012 in Paris (France), we assessed hemoglobin levels (g/dl), depressive symptoms and antidepressant intake. We examined the association of both depression and antidepressant intake with hemoglobin level, adjusting for numerous socio-demographic and health variables. We also assessed the association with specific antidepressant classes. Depression and anti-depressant intake were independently associated with lower hemoglobin level (beta = -0.074; p = .05 and beta = -0.100; p = .02 respectively in the fully-adjusted model). Regarding antidepressant classes, selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) intake were associated with lower hemoglobin level (beta = -0.11; p = .01). To conclude, both depression and antidepressant intake were associated with lower hemoglobin level. In particular, as SSRI or SNRIs intake was also related to lower hemoglobin level, these classes should be used with caution in depressed individuals at risk for anemia.",
keywords = "Depression, Hemoglobin, Antidepressant, Cohort study, Epidemiology, SEROTONIN REUPTAKE INHIBITORS, POSTPARTUM HEMORRHAGE, ANEMIA, RISK, ASSOCIATION, SYMPTOMATOLOGY, QUESTIONNAIRE, SYMPTOMS, THERAPY, ADULTS",
author = "Helene Vulser and Cedric Lemogne and Pierre Boutouyrie and Francine Cote and Marie-Cecile Perier and {Van Sloten}, Thomas and Nicolas Hoertel and Nicolas Danchin and Frederic Limosin and Xavier Jouven and Jean-Philippe Empana",
note = "Funding Information: HV reports a research grant from Servier. CL reports consulting or speaker fees from Boehringer-Ingelheim, Janssen, Lundbeck and Otsuka Pharmaceuticals, outside the submitted work. ND has received research grants from Amgen, Astra-Zeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Eli-Lilly, Merck, Pfizer, and Sanofi and fees for lectures or consulting for Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Daiichi-Sankyo, Eli-Lilly, MSD, Novo-Nordisk, Pfizer, Sanofi, and Servier. FL reports consulting, investigator or speaker fees from AstraZeneca, Janssen, Lundbeck, Roche and Servier, and non-financial support from Lundbeck and Otsuka Pharmaceutical. Other authors have no conflicts of interest to declare. Funding Information: The PPS3 Study was supported by grants from The National Research Agency (ANR), the Research Foundation for Hypertension (FRHTA), the Research Institute in Public Health (IRESP) and the Region Ile de France (Domaine d'Int?r?t Majeur). Funding Information: The PPS3 Study was supported by grants from The National Research Agency (ANR), the Research Foundation for Hypertension (FRHTA), the Research Institute in Public Health (IRESP) and the Region Ile de France (Domaine d'Int{\'e}r{\^e}t Majeur). Publisher Copyright: {\textcopyright} 2020",
year = "2020",
month = jun,
doi = "10.1016/j.ypmed.2020.106050",
language = "English",
volume = "135",
journal = "Preventive Medicine",
issn = "0091-7435",
publisher = "Elsevier Science",
}